SML3784
AZ960
≥98% (HPLC)
别名:
(S)-5-Fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile, 5-Fluoro-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-3-pyridinecarbonitrile, AZ 960, AZ-960
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H16F2N6
化学文摘社编号:
分子量:
354.36
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
SMILES string
Fc1c(nc(c(c1)C#N)N[C@@H](C)c3ccc(cc3)F)Nc2[nH]nc(c2)C
InChI
1S/C18H16F2N6/c1-10-7-16(26-25-10)23-18-15(20)8-13(9-21)17(24-18)22-11(2)12-3-5-14(19)6-4-12/h3-8,11H,1-2H3,(H3,22,23,24,25,26)/t11-/m0/s1
InChI key
SUNXHXDJOIXABJ-NSHDSACASA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
ATP-competitive, potent and selective Janus-associated kinase 2 (JAK2) inhibitor.
AZ960 is an ATP-competitive, potent and selective Janus-associated kinase 2 inhibitor (JAK2 Ki = 0.45 nM with 15 μM ATP, 96% inhibition at 10 nM) with additional lower potency against TrkA/Aurora-A/ARK5 (91/73/65% inhibition at 10 nM; IC50 >100 nM against 72 other kinases). AZ960 exhibits JAK2-selective anti-proliferation potency (GI50 = 25, 214, 230, 279 nM using cells expression TEL-JAK2, -Tyk2, -JAK1, -JAK3, respectively) and inhibits cellular STAT5 phosphorylation in TEL-JAK2-expressing cells (IC50 = 15 nM) at a 15–30-fold potency than the TEL-JAK1, -JAK3, and -Tyk2 transfectants.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor
Bioorganic & Medicinal Chemistry, 24(19), 4647-4651 (2016)
AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells
Molecular Cancer Therapeutics, 9(12), 3386-3395 (2010)
Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2
The Journal of Biological Chemistry, 283(47), 32334-32343 (2008)
Identifying a confused cell identity for esophageal squamous cell carcinoma
Signal transduction and targeted therapy, 7(1), 122-122 (2022)
Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/?-catenin-driven hepatocellular carcinoma
Journal of Hepatology, 72(1), 104-118 (2020)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持